Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
This article was originally published in The Tan Sheet
Executive Summary
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
You may also be interested in...
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
Public Citizen petitions FDA to add several warnings to all proton pump inhibitors, including OTCs – which the agency previously determined do not pose the same level of risk as prescription versions.
Homeopathics, Supplements, OTC Medicines Overlap In Pharmacists’ ‘Over-The-Counter’ Survey
Results of U.S. News & World Report’s first “Best OTC Medicine & Health Products” survey include homeopathic formulations, supplements and non-drug topicals in same categories of indications with nonprescription pharmaceuticals.
NMN Supplement Firm Works On Disclosing Sales Relationships With Advertising Affiliates
Renue By Science agrees with National Advertising Division recommendations to “clearly and conspicuously disclose” material connections in online advertising by employees, nonprofits and others offering sales to its supplements containing nicotinamide mononucleotide, quercetin or resveratrol.